BREAKING: GW Pharma Sees Volatility on Epilepsy Abstract

GW Pharma (GWPH) plunged today before quickly recovering some of the losses following the release of an abstract of a study published to the American Epilepsy Society website in advance of its annual meeting to be held in early December.

The report discussed 25 patients enrolled in an observational study, concluding:

Add-on pure CBD was associated with more than 50% seizure reduction in one-third of patients at 3 months. This substantial improvement in seizure control was maintained in 40% of patient for 12 months. Best results were obtained in patients with Dravet syndrome, although one experienced a severe increase in seizure frequency.

The report seems to actually be favorable, indicating that Epidiolex is helpful to many patients whom have had trouble controlling seizures with other pharmaceuticals.

The price action today shows the impact of the news:

GWPH 111915

Breaking News by Alan Brochstein, CFA
Alan Brochstein, CFA
Based in Houston, Alan leverages his experience as founder of online community 420 Investor, the first and still largest due diligence platform focused on the publicly-traded stocks in the cannabis industry. With his extensive network in the cannabis community, Alan continues to find new ways to connect the industry and facilitate its sustainable growth. At New Cannabis Ventures, he is responsible for content development and strategic alliances. Before shifting his focus to the cannabis industry in early 2013, Alan, who began his career on Wall Street in 1986, worked as an independent research analyst following over two decades in research and portfolio management. A prolific writer, with over 650 articles published since 2007 at Seeking Alpha, where he has 70,000 followers, Alan is a frequent speaker at industry conferences and a frequent source to the media, including the NY Times, the Wall Street Journal, Fox Business, and Bloomberg TV. Contact Alan: Twitter | Facebook | LinkedIn | Email

Get Our Sunday Newsletter